Quetiapine extended release tablet + Placebo
ApprovedCompleted 0 watching 0 views this week🔥 Hot
85
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Primary Anxiety Disorders
Conditions
Primary Anxiety Disorders, Mood Disorders With Comorbid Anxiety Symptoms
Trial Timeline
May 1, 2009 → Jul 1, 2010
NCT ID
NCT00912535About Quetiapine extended release tablet + Placebo
Quetiapine extended release tablet + Placebo is a approved stage product being developed by AstraZeneca for Primary Anxiety Disorders. The current trial status is completed. This product is registered under clinical trial identifier NCT00912535. Target conditions include Primary Anxiety Disorders, Mood Disorders With Comorbid Anxiety Symptoms.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00912535 | Approved | Completed |
Competing Products
20 competing products in Primary Anxiety Disorders